Abstract:Introduction: Genetic testing is a cornerstone in the assessment of many cardiac diseases. However, variants are frequently classified as Variants of Unknown Significance (VUS), limiting the utility of testing. Recently, the DeepMind group (Google, USA) developed AlphaMissense, a unique Artificial Intelligence (AI) based model, based on language model principles for the prediction of missense variant pathogenicity. Objective: To report on the performance of AlphaMissense, accessed by VarCardio, an open web-based variant annotation engine, in a real-world cardiovascular genetics center. Methods: All genetic variants from an inherited arrhythmia program were examined using AlphaMissense via VarCard.io and compared to the ClinVar variant classification system, as well as another variant classification platform (Franklin by Genoox). The mutation reclassification rate and genotype phenotype concordance were examined for all variants in the study. Results: We included 266 patients with heritable cardiac diseases, harboring 339 missense variants. Of those, 230 (67.8%) were classified by ClinVar as either VUS or non-classified. Using VarCard.io, 198 VUSs (86.1%, CI 80.9-90.3%) were reclassified to either Likely Pathgenic (LP) or Likely benign (LB). The reclassification rate was significantly higher for VarCard.io than for Franklin (86.1% vs 34.8%, p<0.001). Genotype-Phenotype concordance was highly aligned using VarCard.io predictions, at 95.9% (CI 92.8-97.9%) concordance rate. For 109 variants classified as Pathogenic, LP, Benign or LB by ClinVar, concordance with VarCard.io was high (90.5%). Conclusion: AlphaMissense, accessed via VarCard.io, may be a highly efficient tool for cardiac genetic variant interpretation. The engine's notable performance in assessing variants that are classified as VUS in ClinVar, demonstrates its potential to enhance cardiac genetic testing. Introduction: Genetic testing is a cornerstone in the assessment of many cardiac diseases. However, variants are frequently classified as Variants of Unknown Significance (VUS), limiting the utility of testing. Recently, the DeepMind group (Google, USA) developed AlphaMissense, a unique Artificial Intelligence (AI) based model, based on language model principles for the prediction of missense variant pathogenicity. Objective: To report on the performance of AlphaMissense, accessed by VarCardio, an open web-based variant annotation engine, in a real-world cardiovascular genetics center. Methods: All genetic variants from an inherited arrhythmia program were examined using AlphaMissense via VarCard.io and compared to the ClinVar variant classification system, as well as another variant classification platform (Franklin by Genoox). The mutation reclassification rate and genotype phenotype concordance were examined for all variants in the study. Results: We included 266 patients with heritable cardiac diseases, harboring 339 missense variants. Of those, 230 (67.8%) were classified by ClinVar as either VUS or non-classified. Using VarCard.io, 198 VUSs (86.1%, CI 80.9-90.3%) were reclassified to either Likely Pathgenic (LP) or Likely benign (LB). The reclassification rate was significantly higher for VarCard.io than for Franklin (86.1% vs 34.8%, p<0.001). Genotype-Phenotype concordance was highly aligned using VarCard.io predictions, at 95.9% (CI 92.8-97.9%) concordance rate. For 109 variants classified as Pathogenic, LP, Benign or LB by ClinVar, concordance with VarCard.io was high (90.5%). Conclusion: AlphaMissense, accessed via VarCard.io, may be a highly efficient tool for cardiac genetic variant interpretation. The engine's notable performance in assessing variants that are classified as VUS in ClinVar, demonstrates its potential to enhance cardiac genetic testing.

Assessing concordance among human, in silico predictions and functional assays on genetic variant classification.

Accuracy Of Cnv Detection From Gwas Data

A Comparison on Predicting Functional Impact of Genomic Variants.

Toward Automatic Variant Interpretation: Discordant Genetic Interpretation Across Variant Annotations for ClinVar Pathogenic Variants

Performance Comparison of Computational Methods for the Prediction of the Function and Pathogenicity of Non-Coding Variants

DVA: Predicting the Functional Impact of Single Nucleotide Missense Variants

Improved Detection of Rare Genetic Variants for Diseases

Assessment of variant effect predictors unveils variants difficulty as a critical performance indicator

Prediction of disease-associated functional variants in noncoding regions through a comprehensive analysis by integrating datasets and features

Identifying noncoding risk variants using disease-relevant gene regulatory networks

Predicting Regulatory Variants with Composite Statistic

Combining Artificial Intelligence: Deep Learning with Hi-C Data to Predict the Functional Effects of Non-Coding Variants.

X-CNV: genome-wide prediction of the pathogenicity of copy number variations

Abstract 4884: Evaluating the utility of in silico variant annotation tools for cancer driver detection

Systematic assessment of structural variant annotation tools for genomic interpretation

Prediction of Deleterious Single Amino Acid Polymorphisms with a Consensus Holdout Sampler

Accurate Prediction Of Functional Effects For Variants By Combining Gradient Tree Boosting With Optimal Neighborhood Properties

QAFI: a novel method for quantitative estimation of missense variant impact using protein-specific predictors and ensemble learning

A computational method for identification of disease-associated non-coding SNPs in human genome

AI-derived comparative assessment of the performance of pathogenicity prediction tools on missense variants of breast cancer genes

Performance of a Protein Language Model for Variant Annotation in Cardiac Disease